AI Image
GLP-1 makers Novo, Eli Lilly sued over sudden loss of vision in patients
NewsNation • • business
Key Points:
- Patients are suing manufacturers Novo (Wegovy, Ozempic) and Eli Lilly (Zepbound) over sudden vision loss linked to GLP-1 weight-loss drugs, alleging inadequate warnings about the risk.
- The vision loss condition involved is nonarteritic anterior ischemic optic neuropathy (NAION), which can cause sudden and often permanent vision impairment.
- Some research suggests GLP-1 drugs may increase the risk of NAION, and certain countries require warning labels, but the U.S. FDA has not mandated such warnings and is currently investigating the potential link.
- Tracking the connection between GLP-1 drugs and NAION is complicated because NAION lacks a specific diagnosis code, and many patients have other health issues like diabetes and heart disease that independently increase NAION risk.
